Patients whose lives were ruined after being ‘needlessly given cancer drug for years’ sue NHS trust
More than 20 patients who say that their quality of life is ruined when they are given unnecessarily, a high toxic cancer drug is suing for the relevant NHS trust.
Some people were prescribed temosolomide, which should normally be used for only six months. University hospitals have been more than ten years during treatment by Coventry and Warwickshire NHS Trust.
They say that over -prescribed people leave them with side effects, including secondary cancers and disabled fatigue.
Earlier this year, the maintenance quality commission was looking for at least 14 cases, but lawyers always say that more.
An investigation by lawyers Brabners has found that many patients with brain and spine tumors under the care of Professor Ian Brown in the last twenty years have been subjected to “unnecessary and unnecessary use of chemotherapy, which had serious side effects, including excessive fatigue, confusion, diseases and seizures.
Temosolomide time periods, allegedly contrary to medical and scientific guidelines, are given. The standard NHS procedure is to use the drug for six months and the drug manufacturer recommends it to be used up to 12 months.
A man said that he had been prescribed for about two years longer than necessary, and as a result he suffered excessive fatigue and low mood.
A woman in her twenty woman said she had been misdirained by cancer and took the drug unnecessarily for about eight years.
Lawyers claim that some patients have treatment for secondary cancers, allegedly linked to the excessive use of temosolomidine.
Others claimed that long -term use could not follow career ambitions and normal daily activities, because chemotherapy weakens with a long recovery time. Some have reported results of fertility or abnormal blood test results.
The legal team shows that the data shows that confidence spent from 2009 to 2024 to £ 3.6 million, and that other NHS oncology departments are 10 times.
Lawyers are now calling for an extended patient safety and independent investigation focusing on the treatment focused by patients under Prof of Brown, especially in 2006.
Güven conducts an internal patient safety covering with 2017-2023, when Prof Brown retired.
Only a patient, who was defined as Michael, received 22 safe cycles temosolomide despite their scanning.
Prof Brown was not present during consultations, and Michael said it was always seen by a clinical nurse expert.
After excessive fatigue and low mood, according to his lawyers, he learned that he should not be treated for so long, not from confidence, not from confidence.
Another patient, who is just defined as Becky, says that he has taken at least 100 cycles of the drug unnecessarily after being wrongly diagnosed with a brain tumor.
Fiona Tinsley, the Head of Medical Neglect in Brabners, said: “The scope of this scandal and the physical and mental impact on Prof Brown patients cannot be underestimated.”
“We believe that there is much more patients who have not yet come to the fore and unfortunately have passed away.
“While welcoming the investigations carried out by the General Medical Council and the Royal Doctors College, we believe that a full independent investigation, including the extension of trust until 2006, is necessary – processes are put forward not only to provide justice for victims, but to better identify and prevent such failures again.”
Confidence spokesman Independent: “At the end of 2023 to ensure that appropriate support and maintenance plans are available, we have reviewed and talked extensively on all individuals receiving the treatment of tempozolomide (TMZ).
“A glioblastoma is an aggressive brain tumor with less than two percent of patients survived for more than 10 years. This is extremely complex and the risk of all treatment modes-chemotherapy and radiotherapy-complication and side effects.
“National Health and Care Excellence Institute (NICE) guidelines acknowledge that clinicians can use professional judgments in accordance with individual conditions while presenting treatment to patients.
“Between 2017-2023, we have assigned the Royal College to conduct an independent examination of a representative cohort of patients receiving 12 cycles Adjuvan TMZ.
“As this process continues, it will not be appropriate to make more comments at this stage.”
It is understood that CQC inspectors are in contact with confidence in order to understand the details and to seek the assurance that patients are not at risk. The regulator will examine more information to judge whether it is necessary to be included.
